Brian P Monahan
Overview
Explore the profile of Brian P Monahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mansky P, Wallerstedt D, Sannes T, Stagl J, Johnson L, Blackman M, et al.
Evid Based Complement Alternat Med
. 2013 Nov;
2013:964592.
PMID: 24285980
Purpose: European Mistletoe (Viscum album L.) extracts (mistletoe) are commonly used for cancer treatment in Europe. This phase I study of gemcitabine (GEM) and mistletoe in advanced solid cancers (ASC)...
2.
Bremer C, Monahan B
Curr Gastroenterol Rep
. 2006 Jul;
8(4):333-41.
PMID: 16836946
Neutropenic enterocolitis (NE) must be recognized in patients with fever, neutropenia, and abdominal pain. Classically, NE has been described in patients with hematologic malignancies treated with intensive chemotherapy. Current interest...
3.
Wright M, Morrison G, Lin P, Leonard G, Nguyen D, Guo X, et al.
Clin Cancer Res
. 2005 Jun;
11(11):4144-50.
PMID: 15930350
Purpose: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated...
4.
Mansky P, Grem J, Wallerstedt D, Monahan B, Blackman M
Integr Cancer Ther
. 2004 Jan;
2(4):345-52.
PMID: 14713326
Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to...
5.
Grem J, Quinn M, Keith B, Monahan B, Hamilton J, Xu Y, et al.
Cancer Chemother Pharmacol
. 2003 Sep;
52(6):487-96.
PMID: 12955469
Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial....
6.
Takimoto C, Remick S, Sharma S, Mani S, Ramanathan R, Doroshow J, et al.
J Clin Oncol
. 2003 Jul;
21(14):2664-72.
PMID: 12860942
Purpose: This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in...
7.
Leonard G, Battiwalla M, Stockle J, Harris R, Monahan B, Grem J
Lancet Oncol
. 2003 Jun;
4(6):358.
PMID: 12788408
No abstract available.
8.
Guo X, Harold N, Saif M, Schuler B, Szabo E, Hamilton J, et al.
Cancer Chemother Pharmacol
. 2003 Apr;
52(1):79-85.
PMID: 12707718
Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received...
9.
Grem J, Harold N, Keith B, Chen A, Kao V, Takimoto C, et al.
Clin Cancer Res
. 2002 Jul;
8(7):2149-56.
PMID: 12114415
Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases I and II through a mechanism distinct from other topoisomerase poisons. PZA shows schedule-independent...